– SWITZERLAND, Schlieren – Anjarium Biosciences AG, a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announced the appointments of Dr. Gaurav Shah, (M.D.) and Dr. Doug Fambrough (Ph.D.) to its Board as Independent Non-Executive Directors.
Gaurav Shah has also been named as Chair of the Board of Directors.
“I am thrilled that Gaurav and Doug, two highly experienced biotech leaders, will be joining the Anjarium Board. Their combined experience in growing innovative gene therapy companies and the breadth of their strategic and operational expertise will be highly valuable at this formative time for Anjarium. Their appointments further strengthen a Board that represents a vast range of specialisms that will be vital to Anjarium’s future success.” said CEO, Stephen Yoo.
About Dr. Gaurav Shah
Gaurav Shah is an experienced gene therapy leader with over 15 years of experience in the biopharmaceutical industry. He is the founding CEO of Rocket Pharma, which is developing gene therapies for rare inherited diseases incorporating both adeno-associated viral vector (AAV) and lentiviral vector (LVV) approaches. Before Rocket Pharma, he served as Global Program Head in the Cell & Gene Therapies Unit at Novartis where he led the pivotal CAR-T studies for patients with leukemia and lymphoma.
Gaurav started his career in the industry at ImClone, a subsidiary of Eli Lilly, as a Medical Director, responsible for the clinical development of novel monoclonal antibodies in oncology.
Gaurav Shah said: “I am delighted to join the Board of Directors at Anjarium. The Company has an innovative approach to non-viral gene therapy and its unique Hybridosome® technology demonstrates significant potential to optimize gene therapies for serious genetic diseases. I look forward to working with the experienced Board and Anjarium’s expert leaders in advancing a promising pipeline of gene therapies that could have a real impact on patients.”
He received his MD from Columbia University and also holds a degree in Behavioral Neuroscience from Harvard University. He completed his internal medicine residency at Brigham and Women’s Hospital and oncology fellowship training at Memorial-Sloan Kettering.
About Dr. Douglas Fambrough
Doug Fambrough co-founded Dicerna, a company developing medicines to selectively silence disease-causing genes using RNA interference (RNAi). He served as Dicerna’s President and CEO for almost 12 years, successfully leading the company through a highly successful IPO, multiple major corporate collaborations, and ultimately through its $3.3 billion acquisition by Novo Nordisk in 2021. Before Dicerna, Doug was a General Partner at Oxford Bioscience Partners where he had a strong track record leading investments in life science technology companies. His investments include first-generation RNAi pioneer Sirna Therapeutics, which was acquired by Merck, and Solexa, inventor of the world’s dominant DNA sequencing platform, which was acquired by Illumina.
Douglas Fambrough commented: “Conventional viral-vector based gene therapies have several limitations, and new approaches are needed to provide patients with more predictable and enduring, re-dosable treatments. Over the last yea,r Anjarium has demonstrated exciting progress in building its business and developing its non-viral gene therapy platform, positioning it well for success in this exciting space.”
Doug holds aPh.D.D in Genetics from the University of California, Berkeley, and an AB degree in Biology from Cornell University.
About Anjarium Biosciences
Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient’s lifetime. The Company’s versatile platform aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector-based gene therapies.
For more information: https://www.anjarium.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
